Kisspeptin-10 Price Comparison — Compare 21 Vendors

View full research →
Testosterone and LH optimizationSafety Rating 7/10

Price Comparison

Compare vendors · per 10mg

21 vendors competing

VendorPrice$ / mgUpdated
Ascension Peptides8.5/10$29.00$58.00−50% · code peptidepri$2.90Apr 16, 2026Buy →
Puratek Peptides9.5/10$35.96$39.95−10% · code PEPTIDEPRICES$3.60May 19, 2026Buy →
Hydro Research9/10$36.00$45.00−20% · code PEPTIDEP20$3.60Jun 5, 2026Buy →
Glacier Aminos9.5/10$36.89$40.99−10% · code peptidep$3.69Jun 23, 2026Buy →
CertaPeptides7.5/10$36.90$41.00−10% · code PEPTIDEPRICES$3.69Jun 27, 2026Buy →
SomaChems7/10$47.99$59.99−20% · code PEPTIDEPRICES$4.80May 14, 2026Buy →

Research details

Kisspeptin-10 — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range100–500 mcg SC once or twice daily. Some pulse protocols mimic LH surges. Cycle 4–8 weeks.
AdministrationSubcutaneous injection
Safety7/10 · Not FDA-approved (research)
NCAA D1Banned

Overview

About Kisspeptin-10

Mechanism of action

Endogenous neuropeptide; binds KISS1R (GPR54); potent stimulator of GnRH release, driving LH and FSH surges; key regulator of reproductive axis; also inhibits cancer metastasis.

Safety profile

Injection site reactions; potential LH/FSH overstimulation. Generally well-tolerated. Long-term data limited. · Multiple human clinical studies; well-tolerated; short-acting; no serious adverse events

📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Kisspeptin-10

Research

Studies & key findings

  • Kisspeptin-10, the shortest bioactive form of kisspeptin (a GPR54/KISS1R ligand), robustly stimulates LH pulse frequency in healthy men at all tested IV doses; a continuous infusion of 1.5 µg/kg/h increased LH pulse frequency and significantly elevated testosterone, identifying its therapeutic potential as an LH/testosterone axis modulator.
  • Responsiveness to kisspeptin-10 shows pronounced sexual dimorphism: robust LH/FSH release occurs in men at all cycle phases and in women only during the preovulatory phase — not during the follicular phase — indicating cycle-phase sensitivity must be accounted for in reproductive disorder treatment protocols.

7 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch